Yale School of Medicine research team finds evidence supporting the use of oxytocin as a treatment for autism spectral disorder.
The Strittmatter Lab has uncovered the hidden protein that serves as the intermediary in the downward spiral towards Alzheimer’s disease; this protein is the target for one of the most innovative drug interventions to date.
Bacteria all around us produce an endless variety of bioactive small molecules. Yale Chemistry Professor, Jason Crawford, has harnessed rapid sequencing technology to mine the bacterial genome in search of novel natural products for drug development.
A Yale-led study has found that SIV, which causes AIDS in various non-human primates, leads to disruption of gut microbiome that may give rise to many of the deadly infections that compromise host health.
Yale researchers’ recent study published in PLOS Pathogens will help us treat Dengue fever, a growing international public health issue.
Idiopathic Pulmonary Fibrosis is one of mankind’s deadliest and most mysterious lung diseases. A new study led by Yale School of Medicine, however, is beginning to shed light on IPF’s previously uncharted territory.
Novel technique uses computers, rather than scalpels, to identify specific genes related to kidney disease.
A clinical trial led by Yale professor Kevan Herold may lead to an effective new treatment for type 1 diabetes.
Why is the TB/HIV dual epidemic so pervasive in sub-Saharan Africa? Dr. Richard Bucala’s research at the Yale School of Medicine suggests genetics holds the answer.
In a collaborative study, researchers from several Yale departments have developed small synthetic molecules that limit damage to the heart from ischemia, which could potentially be developed into drugs to be used in a surgical or therapeutic setting.